EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Straumann Holding AG (STMN) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Straumann Holding AG CHF 45.50, price CHF 96.38, upside -52.8%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · CH · ISIN CH1175448666

SH Straumann Holding AG logo Broad data Sep 25, 2026

Straumann Holding AG

STMN · SW

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value CHF 45.50 · Strongly overvalued (−53%)
✓Quality 66/100
✓Healthy Growth (revenue 5y +12.8 %/yr)
✓Solidly profitable · 13.7% net margin (TTM)
✓Low debt · generates free cash flow
·1.04% dividend yield
!Trails peers (5/15)
✓Wide moat 69/100
!Insider activity 40/100
!Weak on future: 11 out of 100
!Weak on dividend: 21 out of 100
Watch Straumann Holding AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 199.75 CHF 74.97 Fair Value CHF 45.50 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 25, 2026.

How to read this chart

60‑month range CHF 74.97 – CHF 199.75 · fair‑value band CHF 28.93 – CHF 59.15 · the CHF 96.38 price screens above the CHF 45.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 25, 2026.

Follow Straumann Holding in your weekly email

Every Wednesday you see whether Straumann Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Straumann Holding AG provides tooth replacement and orthodontic solutions in Switzerland, the United States, China, Germany, Brazil, Japan, France, and internationally. It operates through Sales Europe, Middle East and Africa; Sales North America; Sales Asia Pacific; Sales Latin America; and Operations segments.

Show more

Straumann Holding AG provides tooth replacement and orthodontic solutions in Switzerland, the United States, China, Germany, Brazil, Japan, France, and internationally. It operates through Sales Europe, Middle East and Africa; Sales North America; Sales Asia Pacific; Sales Latin America; and Operations segments. The company offers dental implants, instruments, CADCAM prosthetics, orthodontic and clear aligners, biomaterials, and digital equipment and solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. It also provides implant systems, components, and related instruments, as well as healing components, materials and surfaces, surgical sets and instruments, and guided surgery and navigation products; prosthetics, including angled solutions, connections, components, and molar solutions; intra-oral and lab scanners, milling machines, dynamic navigation systems, and 3D printers; consumables, such as blocks, discs, resins, titanium bases, and abutment blanks, as well as scan bodies, analogs, and sleeves; online education; and dentists and dental labs solutions. In addition, the company offers regenerative solutions for tooth preservation, implant-site management, and implant preservation; scanner hardware, software licenses, sterile-packaged products, customer training, and other products; and logistics and supply chain services. Further, it provides thermoplastics; implant treatment referral; high-tech materials; artificial intelligence solutions for dental applications; and 3D orthodontic treatment animations. The company sells its products under the Straumann, Neodent, Medentika, Anthogyr, ClearCorrect, NUVO, and other brands through a network of distribution subsidiaries and partners, and third-party distributors, as well as through its e-shop. It serves clinicals needs, patient segments, and healthcare systems. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

Stock analysis

Straumann Holding AG (STMN) currently trades at CHF 96.38, while our model-based Fair Value estimate is CHF 45.50, implying the stock looks roughly 111.8% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of CHF 48.01 per share, and 0 of the 26 models we run sit above the CHF 96.38 price.

Bear case: the Asset-Based group reads lowest at CHF 9.08, and 26 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: CHF 28.93 (bear) to CHF 59.15 (bull), the price of CHF 96.38 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Straumann Holding AG reported revenue of CHF 2.6B in FY2025 versus CHF 2.0B in FY2021, a compound +6.5%/yr. Reported net income was CHF 358M in FY2025, compounding −2.5%/yr from FY2021.

Key figures

Market cap CHF 16.7B · P/E ratio 43.2 · P/S ratio 5.94 · EPS (TTM) CHF 2.23 · Dividend yield 1.0% · Net margin 13.7% · Return on equity 17.0% · Return on assets (EBIT) 15.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 11% below its 52-week high and 29% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −53%, STMN screens richer than that median.

Fair Value models

Bear CHF 28.93 Fair Value CHF 45.50 Bull CHF 59.15
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (CHF 0.9031 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF CHF 26.64 CHF 42.31 CHF 67.11 79
Growth DCF CHF 26.91 CHF 40.46 CHF 60.39 78
Owner Earnings CHF 27.43 CHF 43.60 CHF 69.17 75
All 26 models by family
DCF Models
FCF DCF CHF 26.64 CHF 42.31 CHF 67.11 79
Owner Earnings CHF 27.43 CHF 43.60 CHF 69.17 75
5Y Revenue Exit CHF 29.89 CHF 49.39 CHF 74.81 72
5Y EBITDA Exit CHF 37.59 CHF 64.18 CHF 95.97 74
5Y P/E Exit CHF 31.95 CHF 53.34 CHF 76.36 70
10Y Revenue Exit CHF 27.51 CHF 45.22 CHF 70.10 66
10Y EBITDA Exit CHF 33.46 CHF 55.64 CHF 86.66 67
10Y P/E Exit CHF 29.82 CHF 48.01 CHF 71.31 63
Earnings-Based
Graham-Dodd CHF 15.27 CHF 53.79 CHF 72.36 64
Lynch FV CHF 12.57 CHF 17.96 CHF 23.35 61
PEG = 1.0 CHF 12.57 CHF 17.96 CHF 23.35 57
EPV CHF 28.41 CHF 32.91 CHF 36.85 74
Dividend Discount
Gordon GGM CHF 8.71 CHF 18.12 CHF 28.75 66
DDM Multi-Stage CHF 8.71 CHF 15.28 CHF 19.02 66
Multiples
P/E Multiple CHF 37.05 CHF 49.39 CHF 61.74 63
P/S Multiple CHF 28.63 CHF 38.17 CHF 47.71 58
P/B Multiple CHF 28.63 CHF 38.17 CHF 47.71 55
EV/EBIT CHF 45.31 CHF 59.95 CHF 74.58 66
EV/EBITDA CHF 47.98 CHF 63.50 CHF 79.02 67
EV/Revenue CHF 32.75 CHF 46.18 CHF 59.60 54
Asset-Based
NCAV (Graham) CHF 6.77 CHF 9.08 CHF 13.55 54
Growth DCF
Growth DCF CHF 26.91 CHF 40.46 CHF 60.39 78
Rev-Margin DCF CHF 29.89 CHF 49.13 CHF 71.95 72
Economic Profit
Residual Income CHF 14.72 CHF 18.93 CHF 51.54 67
ROIC Compounder CHF 30.75 CHF 38.88 CHF 48.45 72
Growth Earnings
Growth-Adj P/E CHF 31.85 CHF 45.50 CHF 59.15 67

Open the full fair value analysis →

Notify me when STMN reaches fair value

Put STMN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 66/100

Of which business quality 66 · Market factors (momentum, volatility) 48

Profitability 63
Margins and returns on capital today
Quality Growth 27
Are margins and returns improving?
Cashflow 60
Earnings quality: real cash, not paper profit
Fin. Strength 84
Balance sheet, leverage, solvency risk
Investment 75
Disciplined investing over empire-building
Low Volatility 48
Calm price path (market factor)
Momentum 45
Price trend over the last 3–12 months (market factor)
52W Momentum 53
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 98/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+4.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.8%
Start year 2020 (pandemic). Over 10 years: +12.6% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+4.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.1%
Dividend (yield on the price)1.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3% vs 8%, slowing
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.25% → 21%
Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (Switzerland: IMF forecast 0.6% a year to 2030, 0.8% from 2016 to 2025) that is about +25.1% a year for the price and +7.1% for the forecasts.
Forecast 2026 (sales)+5.6%
Forecast 2027 (sales)+9.7%
Projected 2028 (sales)+8.7%
Projected 2029 (sales)+7.8%
Projected 2030 (sales)+6.8%

STMN screens 112% overvalued. Compare with Intuitive Surgical, Inc →

Compare Straumann Holding AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 204 stocks

Beats the industry median on 5/15 measures
Overall it trails its industry peers.
Valuation
Quality Score 66 · Top 25%
Fair Value upside −53% · Bottom 25%
Profitability
Return on equity (TTM) 17% · Top 25%
Return on assets 11% · Top 25%
Net margin (TTM) 14% · Above median
Operating margin (TTM) 24% · Top 25%
Growth and dividend
Revenue growth 2% · Below median
Dividend yield (TTM) 1.0% · Below median
Balance sheet
Debt / equity 0.12× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 43.2× · Pricier than median
P/B 9.31× · Priciest 25%
P/S (TTM) 7.72× · Priciest 25%
P/FCF 61.0× · Priciest 25%
EV/EBITDA 26.5× · Priciest 25%
PEG 1.57× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 14
FUTURE (revenue growth)11 · sector 31
PAST (return on equity)68 · sector 25
HEALTH (low debt)94 · sector 96
DIVIDEND (yield)21 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $399.52 $348.72 −13%
EssilorLuxottica Société anonyme EL €144.70 €159.17 +10%
Medline Inc MDLN $34.30 $30.15 −12%
Becton, Dickinson and Company BDX $182.52 $103.53 −43%
Alcon Inc ALC $65.39 $39.78 −39%
ResMed Inc RMD A$31.70 A$34.87 +10%
West Pharmaceutical Services, Inc WST $375.87 $137.28 −63%
Sartorius Stedim Biotech S.A DIM €215.80 €54.82 −75%
Solventum Corporation SOLV $88.75 $130.51 +47%
The Cooper Companies, Inc COO $56.07 $61.68 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Straumann Holding AG · Fair Value
CHF 45.50 −112%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Straumann Holding AG Fair Value". https://www.fairvalue-calculator.com/stock/STMN

Frequently asked questions

Is Straumann Holding AG (STMN) overvalued or undervalued?
As of Sep 25, 2026, our model estimates a fair value of CHF 45.50 versus a price of CHF 96.38, about −53% upside (overvalued).
What is the fair value of STMN?
Our model-based fair value for Straumann Holding AG is CHF 45.50 (as of Sep 25, 2026), built from audited fundamentals. The current price: CHF 96.38.
What is the quality score of STMN?
Straumann Holding AG has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Straumann Holding AG (STMN)?
Our model-based price target is the fair value of CHF 45.50 (as of Sep 25, 2026) from 26 valuation models. Cautious scenario CHF 28.93, optimistic scenario CHF 59.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Straumann Holding AG stock forecast for 2026?
Our models put fair value at CHF 45.50, about −53% upside versus a price of CHF 96.38 (overvalued). Cautious scenario CHF 28.93, optimistic scenario CHF 59.15. The calculation is refreshed regularly with new filings.
What is the revenue of Straumann Holding AG (STMN)?
Straumann Holding AG reported trailing-twelve-month revenue of about CHF 2.6B (latest available figure, as of Sep 25, 2026).
Does Straumann Holding AG pay a dividend?
Straumann Holding AG currently shows a dividend yield of about 1.04% relative to its recent price (as of Sep 25, 2026).
What growth is priced into Straumann Holding AG (STMN)?
For today's price to be fair in a discounted-cash-flow model, Straumann Holding AG would have to grow free cash flow by +25.8 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.8 % per year. As of Sep 25, 2026.
What discount rate (WACC) does the fair value of STMN use?
Our models discount Straumann Holding AG at 9.9 %: a base by market capitalisation (large), damped by beta 1.39, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Straumann Holding AG that is +25.8 % per year a year over ten years, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has Straumann Holding AG (STMN) delivered so far?
Over the past 5 years revenue at Straumann Holding AG grew +12.8 % a year. The price currently implies +25.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Straumann Holding AG (STMN) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Straumann Holding AG (+25.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Straumann Holding AG (STMN)?
The free-cash-flow yield on the price is 2.14 %: that much free cash flow Straumann Holding AG produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Straumann Holding AG (STMN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Straumann Holding AG it is CHF 45.50 per share (as of Sep 25, 2026), against a price of CHF 96.38. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Straumann Holding AG stock overvalued or undervalued in 2026?
As of Sep 25, 2026, STMN trades above its calculated fair value: price CHF 96.38, fair value CHF 45.50, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of STMN?
No. The price is what the market pays today (CHF 96.38); the fair value is what the company's own numbers justify (CHF 45.50). For Straumann Holding AG the two are CHF 50.88 per share apart. That gap is exactly why we show both numbers side by side.
How much is Straumann Holding AG worth?
The market values Straumann Holding AG at about CHF 16.7B (market capitalisation, as of Sep 25, 2026). Per share that is CHF 96.38; our models calculate a fair value of CHF 45.50 per share.
What do the bullish and bearish scenarios say about STMN?
Our models span a range for Straumann Holding AG: cautious scenario CHF 28.93, base CHF 45.50, optimistic CHF 59.15 per share (as of Sep 25, 2026, price CHF 96.38). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of STMN?
Straumann Holding AG trades at a price-to-earnings ratio of 43.2 (as of Sep 25, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 45.50 is built from several models across several years. Other multiples: PEG 1.6, P/B 9.3, P/S 7.7, EV/EBITDA 26.5.
What is the PEG ratio of STMN?
The PEG ratio of Straumann Holding AG is 1.57 (P/E divided by earnings growth, as of Sep 25, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Straumann Holding AG (STMN)?
Balance-sheet figures for Straumann Holding AG (as of Sep 25, 2026): return on equity 17.0%, debt of 0.12 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is STMN from its 52-week high?
Straumann Holding AG trades at CHF 96.38, about 11% below its 52-week high of CHF 108.60 and 29% above the low of CHF 74.97 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 45.50 is for.
Which stocks are comparable to Straumann Holding AG?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Straumann Holding AG stock attractive at the current price?
The data as of Sep 25, 2026: price CHF 96.38, calculated fair value CHF 45.50 (−53%), Quality Score 66/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of STMN calculated?
We run Straumann Holding AG through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 45.50, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Straumann Holding AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Straumann Holding AG (STMN)?
The closing price on Sep 24, 2026 was CHF 96.38. Our model-based fair value is CHF 45.50, about −53% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Straumann Holding AG right now?
The price sits above even our optimistic bull case (CHF 59.15). The favourable scenario is already priced in. Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (CHF 28.93 to CHF 59.15) leaves room in how you read the outcome.
Where does the earnings growth of Straumann Holding AG (STMN) come from?
Earnings per share at Straumann Holding AG grew +8.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +13.2 %, EBIT margin −1.2 %, tax rate −2.4 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Straumann Holding AG

How large is the market capitalisation of Straumann Holding AG (STMN)?
The market capitalisation of Straumann Holding AG is CHF 16.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Straumann Holding AG (STMN)?
The price-to-sales ratio of Straumann Holding AG is 5.94 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Straumann Holding AG (STMN)?
Earnings per share at Straumann Holding AG are CHF 2.23 (price ÷ EPS = P/E 43.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Straumann Holding AG (STMN)?
The dividend yield of Straumann Holding AG is 1.0% (payout 44.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Straumann Holding AG (STMN)?
The net margin of Straumann Holding AG is 13.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Straumann Holding AG (STMN)?
The return on equity (ROE) of Straumann Holding AG is 17.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Straumann Holding AG (STMN)?
On an EBIT basis the return on assets of Straumann Holding AG is 15.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Straumann Holding AG (STMN)?
The operating margin of Straumann Holding AG is 23.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Straumann Holding AG (STMN)?
Revenue at Straumann Holding AG is growing +2.2% versus a year earlier (3y avg +3.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Straumann Holding AG (STMN)?
Earnings per share at Straumann Holding AG are growing −25.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Straumann Holding AG (STMN) carry?
The net debt of Straumann Holding AG is CHF 175M (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Straumann Holding AG in the live analysis

One click puts Straumann Holding AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.